Denis L F Jardim1, Débora de Melo Gagliato2, Gerald Falchook2, Ralph Zinner2, Jennifer J Wheler2, Filip Janku2, Vivek Subbiah2, Sarina A Piha-Paul2, Siqing Fu2, Nizar Tannir3, Paul Corn3, Chad Tang4, Kenneth Hess5, Sinchita Roy-Chowdhuri6, Razelle Kurzrock7, Funda Meric-Bernstam2, David S Hong2. 1. Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address: denis.ljardim@hsl.org.br. 2. Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas M.D. Anderson Cancer Center, Houston, TX. 3. Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. 4. Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX. 5. Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX. 6. Department of Pathology and Laboratory Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX. 7. Department of Medicine, University of California, San Diego, La Jolla, CA.
Abstract
BACKGROUND: The purpose of this study was to determine the prevalence of MET amplification and mutation among GU malignancies and its association with clinical factors and responses to c-MET inhibitors. PATIENTS AND METHODS: Patients with GU malignancies referred to our Phase I Clinical Trials Program were evaluated for MET mutation and amplification and outcomes using protocols with c-MET inhibitors. RESULTS: MET amplification was found in 7 of 97 (7.2%) patients (4/27 renal [all clear cell], 1/18 urothelial, and 2/12 adrenocortical carcinoma), with MET mutation/variant in 3 of 54 (5.6%) (2/20 renal cell carcinoma [RCC] [1 clear cell and 1 papillary] and 1/16 prostate cancer). No demographic characteristics were associated with specific MET abnormalities, but patients who tested positive for mutation or amplification had more metastatic sites (median, 4 vs. 3 for wild type MET). Median overall survival after phase I consultation was 6.1 and 11.5 months for patients with and without a MET alteration, respectively (hazard ratio, 2.8; 95% confidence interval, 1.1 to 6.9; P = .034). Twenty-nine (25%) patients were treated according to a c-MET inhibitor protocol. Six (21%) had a partial response (prostate and RCC) and 10 (34%) had stable disease as best response. Median time to tumor progression was 2.3 months (range, 0.4-19.7) for all treated patients with no responses in patients with a MET abnormality or single-agent c-MET inhibitor treatment. CONCLUSION: MET genetic abnormalities occur in diverse GU malignancies and are associated with a worse prognosis in a phase I setting. Efficacy of c-MET inhibitors was more pronounced in patients without MET abnormalities and when combined with other targets/drugs.
BACKGROUND: The purpose of this study was to determine the prevalence of MET amplification and mutation among GU malignancies and its association with clinical factors and responses to c-MET inhibitors. PATIENTS AND METHODS: Patients with GU malignancies referred to our Phase I Clinical Trials Program were evaluated for MET mutation and amplification and outcomes using protocols with c-MET inhibitors. RESULTS: MET amplification was found in 7 of 97 (7.2%) patients (4/27 renal [all clear cell], 1/18 urothelial, and 2/12 adrenocortical carcinoma), with MET mutation/variant in 3 of 54 (5.6%) (2/20 renal cell carcinoma [RCC] [1 clear cell and 1 papillary] and 1/16 prostate cancer). No demographic characteristics were associated with specific MET abnormalities, but patients who tested positive for mutation or amplification had more metastatic sites (median, 4 vs. 3 for wild type MET). Median overall survival after phase I consultation was 6.1 and 11.5 months for patients with and without a MET alteration, respectively (hazard ratio, 2.8; 95% confidence interval, 1.1 to 6.9; P = .034). Twenty-nine (25%) patients were treated according to a c-MET inhibitor protocol. Six (21%) had a partial response (prostate and RCC) and 10 (34%) had stable disease as best response. Median time to tumor progression was 2.3 months (range, 0.4-19.7) for all treated patients with no responses in patients with a MET abnormality or single-agent c-MET inhibitor treatment. CONCLUSION: MET genetic abnormalities occur in diverse GU malignancies and are associated with a worse prognosis in a phase I setting. Efficacy of c-MET inhibitors was more pronounced in patients without MET abnormalities and when combined with other targets/drugs.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar Journal: Nat Genet Date: 1997-05 Impact factor: 38.330
Authors: Jochen K Lennerz; Eunice L Kwak; Allison Ackerman; Michael Michael; Stephen B Fox; Kristin Bergethon; Gregory Y Lauwers; James G Christensen; Keith D Wilner; Daniel A Haber; Ravi Salgia; Yung-Jue Bang; Jeffrey W Clark; Benjamin J Solomon; A John Iafrate Journal: J Clin Oncol Date: 2011-10-31 Impact factor: 44.544
Authors: L Schmidt; K Junker; N Nakaigawa; T Kinjerski; G Weirich; M Miller; I Lubensky; H P Neumann; H Brauch; J Decker; C Vocke; J A Brown; R Jenkins; S Richard; U Bergerheim; B Gerrard; M Dean; W M Linehan; B Zbar Journal: Oncogene Date: 1999-04-08 Impact factor: 9.867
Authors: Frank Jacobsen; Sharad Nouraie Ashtiani; Pierre Tennstedt; Hans Heinzer; Ronald Simon; Guido Sauter; Hüseyin Sirma; Maria Christina Tsourlakis; Sarah Minner; Thorsten Schlomm; Uwe Michl Journal: Exp Ther Med Date: 2012-10-25 Impact factor: 2.447
Authors: Esther I Verhoef; Kimberley Kolijn; Maria J De Herdt; Berdine van der Steen; A Marije Hoogland; Hein F B M Sleddens; Leendert H J Looijenga; Geert J L H van Leenders Journal: Oncotarget Date: 2016-05-24
Authors: Marco Gymnopoulos; Oscar Betancourt; Vincent Blot; Ryo Fujita; Diana Galvan; Vincent Lieuw; Sophie Nguyen; Jeanette Snedden; Christine Stewart; Jose Villicana; Jon Wojciak; Eley Wong; Raul Pardo; Neki Patel; Francois D'Hooge; Balakumar Vijayakrishnan; Conor Barry; John A Hartley; Philip W Howard; Roland Newman; Julia Coronella Journal: Mol Oncol Date: 2019-12-03 Impact factor: 6.603